Highline Capital Management

Network Bio is a company that specializes in creating a clinical and molecular data library aimed at advancing precision medicine for common human diseases. Its platform serves as a centralized repository for clinical and molecular data, facilitating research by allowing scientists to identify patterns and correlations. This capability is essential for the development of new treatments and diagnostic tools, contributing to more personalized healthcare solutions. Through its innovative approach, Network Bio supports the research community in addressing significant health challenges.

Proscia Inc., established in 2014 and headquartered in Philadelphia, Pennsylvania, specializes in digital pathology informatics through its innovative cloud-based platform. This platform aids in routine pathology operations, enhances cancer diagnosis, and seeks to improve patient outcomes. By leveraging advanced computing technologies, Proscia's solution unlocks hidden data that is not discernible to the human eye, transforming that information into valuable insights. These insights support physicians in accelerating the development of life-saving medical advances, ultimately contributing to a more effective diagnostic process in the field of pathology.

Proscia Inc., established in 2014 and headquartered in Philadelphia, Pennsylvania, specializes in digital pathology informatics through its innovative cloud-based platform. This platform aids in routine pathology operations, enhances cancer diagnosis, and seeks to improve patient outcomes. By leveraging advanced computing technologies, Proscia's solution unlocks hidden data that is not discernible to the human eye, transforming that information into valuable insights. These insights support physicians in accelerating the development of life-saving medical advances, ultimately contributing to a more effective diagnostic process in the field of pathology.

Strata Oncology, Inc. is a precision oncology company focused on enhancing cancer care by facilitating access to precision medicine clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, the company develops a comprehensive precision oncology platform that supports routine testing and efficient use of molecular data. Strata's offerings include The Strata Trial, a genomic testing program for systematic precision oncology implementation, and StrataNGS, a targeted assay for sequencing DNA and RNA from biopsies. Additionally, StrataPOINT integrates electronic medical record histories with molecular profiling to ensure eligible patients are tested and considered for trial enrollment. The company features a portfolio of pharma-sponsored therapeutic protocols, known as Strata Partnered Trials, aligned to specific biomarkers. Strata also operates The Strata Lab, a cancer sequencing facility, and maintains the Strata Precision Oncology Network, a collaborative entity aimed at promoting precision medicine initiatives. Formerly known as Strata Oncology Research, Inc., the company rebranded in 2016 and has been incorporated since 2015.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative therapies for mental health disorders, including depression, anxiety, and substance use disorders. ATAI utilizes psychedelic compounds and other therapeutic methods to address these conditions, collaborating with various partners and research institutions to enhance its drug development pipeline. Its clinical-stage product portfolio features therapies such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and others derived from compounds like MDMA and ibogaine. By working with experts in the field, ATAI aims to ensure the efficacy and safety of its treatments. The company has garnered recognition for its contributions to mental health research and has secured partnerships and funding to further its initiatives in transforming mental health care.

Longboard Pharmaceuticals, Inc., established in 2020 and headquartered in San Diego, California, is engaged in developing optimized medicines targeting neurological diseases. The company focuses on improving pharmacology and pharmacokinetics to create novel treatments for rare conditions. Its pipeline includes LP352, a next-generation 5-HT2C agonist being evaluated for developmental and epileptic encephalopathies; LP143, a centrally acting CB2 receptor full agonist explored for potential treatment of neurological disorders like ALS and PD; and LP659, a highly selective S1P receptor modulator targeting multiple CNS neuroinflammatory disorders. Longboard operates as a subsidiary of Arena Pharmaceuticals, Inc., aiming to deliver these medicines to patients in need.

Passage Bio, Inc. is a genetic medicines company based in Philadelphia, Pennsylvania, dedicated to developing transformative therapies for rare monogenic central nervous system (CNS) diseases. Established in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while taking responsibility for the clinical development, regulatory processes, manufacturing, and commercialization of its product candidates. The partnership also involves research and development collaborations that support the advancement of innovative treatments for these rare disorders.